<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889003</url>
  </required_header>
  <id_info>
    <org_study_id>P16/05_PIO2STOP</org_study_id>
    <nct_id>NCT02889003</nct_id>
  </id_info>
  <brief_title>Second STOP After Pioglitazone Priming in CML Patients</brief_title>
  <acronym>PIO2STOP</acronym>
  <official_title>Combination Study of Pioglitazone and Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia Patients After Failure of a First TKIs Discontinuation Attempt in Order to Prepare a New Stop</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pr Philippe ROUSSELOT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center study, prospective, phase II trial.

      The study objectives are :

        -  To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects
           who experience a loss of MMR following a first TKI discontinuation.

        -  To assess survival without loss of MMR over a 12 months period following a second TKI
           discontinuation in subjects who achieve or maintain &lt; MR4.5 with the combination PIO and
           TKI administered for at least 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Up to 24 months after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment free survival after pioglitazone and tyrosine kinase inhibitor discontinuation.</measure>
    <time_frame>Up to 24 months after inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <arm_group>
    <arm_group_label>CML patients following molecular response loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone + TKI</intervention_name>
    <arm_group_label>CML patients following molecular response loss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CML in any phase. patient in MR4

          2. Loss of MMR following a first or subsequent TKI discontinuation trial.

          3. Patient prior treated with imatinib, dasatinib, nilotinib, or bosutinib

          4. Age &gt;18 years.

          5. Serum bilirubin &lt;1.5 x upper limit of normal values.

          6. AST (SGOT)/ALT (SGPT) &lt;2.5x upper limit of normal values.

          7. Females of child bearing potential must agree to abstain from sexual activity or to
             use a medically approved contraceptive measure/regimen during and for 3 months after
             the treatment period. Women of child bearing potential must have a negative urine
             pregnancy test at the time of enrollment. Acceptable methods of birth control include
             oral contraceptive, intrauterine device, transdermal/implanted or injected
             contraceptives and abstinence.

          8. Males must agree to abstain from sexual activity or agree to utilize a
             medically-approved contraception method during and for 3 months after the treatment
             period.

          9. Signed informed consent.

         10. Be able and willing to comply with study visits and procedures

        Exclusion Criteria:

          1. Known loss of CCyR by marrow cytogenetic or blood FISH for BCR-ABL1.

          2. Loss of CHR.

          3. Participation in another clinical trial with any investigative drug within 30 days
             prior to study enrolment.

          4. Prior allogeneic hematopoietic stem cell transplantation.

          5. Patient requiring anti-diabetic medications to manage hyperglycemia.

          6. Cardiovascular disease: history of congestive heart failure, myocardial infarction
             within the 6 months of study entry, symptomatic cardiac arrhythmia requiring
             treatment.

          7. Hepatic insufficiency

          8. History of bladder cancer.

          9. Diagnosed hematuria.

         10. Known osteoporosis with curative therapy (prophylactic therapy is not an exclusion
             criteria)

         11. Known history of macular edema.

         12. Known history of ABL1-domain mutation associated with resistance to the discontinued
             TKI.

         13. Known allergy to PIO.

         14. Pregnant or breastfeeding.

         15. Use of TZD within 28 days prior to enrollment.

         16. Significant gastrointestinal condition that could potentially impair the absorption or
             disposition of the drug.

         17. Uncontrolled peripheral edema (2+ or more) of any etiology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Noémie DE GUNZBURG, Investigator coordinator</last_name>
    <email>ndegunzburg@ch-versailles.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amina CATTENOY, Project Manager</last_name>
    <email>acattenoy@ch-versailles.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noémie DE GUNZBURG</last_name>
      <email>ndegunzburg@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe ROUSSELOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali TURHAN</last_name>
      <email>ali.turhan@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viviane DUBRUILLE</last_name>
      <email>viviane.dubruille@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine ESCOFFRE-BARBE</last_name>
      <email>Martine.escoffre-barbe@chu-rennes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Dr Noémie DE GUNZBURG</investigator_full_name>
    <investigator_title>Investigator coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

